- The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest’s “Total Cardiac Intelligence” report.
- HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system.
- HeartBeam’s intellectual-property foundation is a major reason for its placement.
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal.
The PatentVest study evaluated 243 companies active in cardiac-diagnostic innovation, scoring each on intellectual-property breadth, technology differentiation and potential for clinical impact. HeartBeam’s second-place ranking reflects its deep patent portfolio and the novelty of its synthesis-ECG architecture, which integrates three distinct noncoplanar dimensions into a synthesized 12-lead signal comparable to standard clinical ECGs. The report identified HeartBeam as one of only a few emerging companies capable of enabling true “total cardiac intelligence,” continuous, portable and clinically accurate cardiac monitoring outside the hospital environment.
HeartBeam’s intellectual-property foundation is a major reason for its placement. The company currently holds 82 global patent publications across 15 patent families covering its foundational technology for card-, watch- and patch-based ECG devices. These patents protect its three-dimensional capture of the heart’s electrical signals and synthesis algorithms, wearable sensor configurations and cloud-based analytics, giving the company a defensible position in the fast-growing field of remote and ambulatory cardiac monitoring. Collectively, this IP portfolio positions HeartBeam among the most comprehensively protected innovators in digital cardiology.
Recognition by PatentVest carries considerable weight because the report benchmarks both legacy and next-generation technology developers, including multinational leaders such as GE Healthcare, Philips and Medtronic. HeartBeam’s placement directly below GE Healthcare and ahead of other major device and software firms underscores its technological credibility despite being an emerging company. The report emphasizes that HeartBeam’s innovation strength lies in its combination of compact form factor, high-fidelity ECG signal synthesis and scalable data-analytics potential, all critical enablers for the shift toward decentralized cardiac care.
The significance of this ranking extends beyond technology. Cardiovascular disease remains the world’s leading cause of death, responsible for an estimated 17.9 million deaths annually according to the World Health Organization, with nearly 85% of those due to heart attacks and strokes. Early detection and monitoring are central to preventing such outcomes, but access to full clinical-grade ECG testing is often limited to clinical settings. HeartBeam’s technology, which is under FDA review to deliver synthesized 12-lead ECG data for arrhythmia assessment from portable devices, can directly target this access gap in the near future, potentially enabling earlier intervention and better patient outcomes.
HeartBeam’s credit-card-sized system is designed for integration into consumer-facing and professional medical devices alike. Its software uses proprietary algorithms to synthesize a full 12-lead ECG view of cardiac electrical activity, empowering physicians to detect arrhythmias once FDA clearance is obtained, as well as detect ischemia and other abnormalities in the near future remotely. By pairing these insights with cloud-based analytics and telemedicine integration, HeartBeam aims to make cardiologist-level interpretation available in primary-care settings, ambulances, and even at home, an advancement that could transform triage and long-term monitoring workflows. In the future, HeartBeam’s core technology will have the ability to be integrated into wearable patches and smartwatch-style form factors, further broadening its reach.
The company’s recognition also comes at a pivotal time for the digital-health industry. The global ECG-monitoring market is projected to grow from $8.62 billion in 2023 to more than $13.94 billion by 2030, driven by increasing prevalence of cardiovascular disorders and rising adoption of remote patient monitoring (https://ibn.fm/rG2z3). The upswing in cardiovascular diseases worldwide, coupled with the growing geriatric population, is one of the primary factors contributing to the market growth. Within that context, HeartBeam’s IP strength and technological differentiation may offer significant competitive advantage as healthcare systems and device manufacturers seek scalable, cost-effective cardiac-monitoring solutions.
HeartBeam leadership team has emphasized that robust intellectual-property protection is core to the company’s mission of redefining cardiac health management. The PatentVest ranking validates this strategy, confirming that HeartBeam’s innovations are not only technologically advanced but also legally defensible across global jurisdictions. This recognition is expected to enhance the company’s visibility with potential partners, investors and healthcare organizations as it continues to commercialize its solutions.
In an industry where innovation can literally save lives, HeartBeam’s ascent to the number-two position worldwide in 12-lead ECG technology highlights both its scientific vision and its execution. By building a robust patent estate and advancing synthesis-ECG capabilities that capture the heart’s signals in full three-dimensional detail, HeartBeam is paving the way toward a future of ubiquitous, clinical-grade cardiac monitoring.
For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Cleared Indications for Use
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (“ECG”) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
